In a research report released Wednesday, Needham’s healthcare analyst Alan Carr reiterated a Buy rating on shares of Genocea Biosciences Inc (NASDAQ:GNCA), with a …
In a research report released Thursday, Needham analyst Alan Carr reiterated a Buy rating on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a price …
In a research report released Friday, Needham analyst Alan Carr reiterated a Buy rating on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and raised the …
Needham’s healthcare analyst Alan Carr came out with some commentary on Intercept Pharmaceuticals Inc (NASDAQ:ICPT), after the company reported second-quarter results and held a conference call …
In a research report released Thursday, Needham analyst Alan Carr reiterated a Buy rating on Cempra Inc (NASDAQ:CEMP) and raised the price target …
On May 19, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced plans for an international Phase 3 trial of OCA in patients with NASH. Although this …
The FDA advisory committee recommended this week that the FDA approve Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s Orkambi therapy to treat cystic fibrosis. By a vote …
Needham’s healthcare analyst Alan Carr weighed in today with an update on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), after the company reported first-quarter financial results and held a …
On May 11, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) reported first quarter earnings for 2015. The biopharmaceutical company does not yet have any approved products …
In a research report released Friday, Needham analyst Alan Carr maintained a Buy rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a $38 price target, after the …
